Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy

Table 2 Results of the univariate and multivariate analyses of progression-free survival in 46 patients with stage III-IV gastric cancer treated with neoadjuvant chemotherapy

Factors	Number	Univariate analysis^a, P value	Multivariate analysis^b,
Factors	Number	Univariate analysis^a, P value	HR (95% CI)	P value
Radicality
R0	37		0.163 (0.063 to 0.421)	<0.001
R1
R2	9	<0.001	1
Differentiation
Differentiated^c	15
Poorly differentiated^d	31	0.039
Pre-chemotherapy blood parameters
Neutrophils, cells/mm³
≤4000	24
>4000	22	0.065
NLR
≤2.5	22		1
>2.5	24	0.012	2.329 (1.069 to 5.073)	0.033
Pre-operative blood parameters e
Neutrophils, cells/mm³
≤4000	34
>4000	12	0.049
NLR
≤2.5	26		1
>2.5	20	0.019	2.347 (1.128 to 4.881)	0.022

HR, hazard ratio; NLR, Neutrophil to lymphocyte ratio.
^aPerformed using the Kaplan-Meier analysis model and log-rank test; values of P<0.10 in the univariate analysis were entered into a multivariate analysis.
^bPerformed using Cox proportional hazards models with the backward likelihood method.
^cDifferentiated include: well and moderately differentiated adenocarcinoma.
^dPoorly differentiated include: poorly differentiated adenocarcinoma, ring cell carcinoma.

ISSN: 1477-7819